Intelligence · Clinical Development
Pipeline search results
Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Placebo
BRIGHT MINDS BIOSCIENCES INC.
Methamphetamine Use Disorder
1 trial -
Placebo
The First People's Hospital of Lianyungang
Asthma
1 trial -
Placebo
BRIGHT MINDS BIOSCIENCES INC.
D-limonene and THC Pharmacodynamics
1 trial -
Placebo - MAD
Hoffmann-La Roche
Healthy Volunteer
1 trial -
Placebo Aprepitant
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Withdrawal
1 trial -
Placebo Intravaginal Ring A
United Therapeutics Europe Ltd
Safety
1 trial -
Placebo Vaginal Film with Square Corners
United Therapeutics Europe Ltd
Safety
1 trial -
Placebo and Oxycodone
BRIGHT MINDS BIOSCIENCES INC.
Hypercapnia
1 trial -
Placebo for Treatment A
Agios Netherlands B.V.
Healthy Volunteers
1 trial -
Placebo for antibiotic
Seres Therapeutics
Metastatic Melanoma
1 trial -
Placebo gelatin pill
Universal Integrated
Vaginosis, Bacterial
1 trial -
Placebo oral capsule
Biogen
Healthy
1 trial -
Placebo pills for 14-day intervention
BRIGHT MINDS BIOSCIENCES INC.
Healthy Controls
1 trial -
Placebo spray and oral moxifloxacin placebo
Jazz Pharmaceuticals Ireland Limited
Effects of Sativex on ECG
1 trial -
REC611-IIT-1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prevention of COVID-19 Caused by SARS-CoV-2
1 trial -
REGN1154 or placebo
Regeneron UK Limited
Healthy Volunteers
1 trial -
Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo
Shanghai University of Traditional Chinese Medicine
Healthy
1 trial -
SNUCPT08_GCPGC
Hospital Authority, Hong Kong
Healthy
1 trial -
Safety for A Phase 1, Randomized, Double-B…
Lacuna Pharma Pty Ltd
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease
1 trial -
TAK-137 5 mg tablet, TAK-137 placebo tablet
Takeda
Healthy Japanese Adult Male
1 trial -
TAK-653 Placebo
NEUROCRINE BIOSCIENCES INC
Depressive Disorder
1 trial -
TAK-951 Placebo
Takeda
Healthy Volunteers
1 trial -
TGD001 SAD study in healthy volunteers
Lacuna Pharma Pty Ltd
A Phase I randomized, double-blind, placebo-controlled study to assess the safety and pharmacokinetics of single-ascending doses of TGD001 in healthy volunteers
1 trial -
TQF3250 placebo
Chia Tai Tianqing Pharmaceutical Group Co.,
Hyperglycemia
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.